Loading...
XNASKPRX
Market cap9mUSD
Dec 27, Last price  
3.24USD
1D
-3.28%
1Q
-5.54%
Jan 2017
98.77%
IPO
-42.65%
Name

Kiora Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:KPRX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
55.52%
Rev. gr., 5y
41.55%
Revenues
0k
0000669,259407,5181,652,5202,686,00012,059000
Net income
-13m
L-7.88%
-6,034,095-3,879,447-1,773,992-8,393,149-13,343,437-13,217,917-10,811,423-7,096,696-8,091,940-16,394,919-13,583,610-12,513,896
CFO
-10m
L-8.35%
-5,221,887-2,957,615-950,617-4,459,169-8,413,180-6,468,541-10,844,512-8,153,833-7,317,169-10,887,672-10,428,133-9,556,951
Earnings
Mar 24, 2025

Profile

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
URL
https://kiorapharma.com/
IPO date
Feb 13, 2015
Employees
12
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
12,717
11,861
10,901
Unusual Expense (Income)
NOPBT
(12,717)
(11,861)
(10,901)
NOPBT Margin
Operating Taxes
90
(113)
(305)
Tax Rate
NOPAT
(12,808)
(11,748)
(10,596)
Net income
(12,514)
-7.88%
(13,584)
-17.15%
(16,395)
102.61%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,154
8,621
18,750
BB yield
-2,189.60%
-343.22%
-5,150.26%
Debt
Debt current
94
106
119
Long-term debt
167
212
300
Deferred revenue
Other long-term liabilities
5,129
3,203
6,519
Net debt
(2,194)
(5,696)
(7,481)
Cash flow
Cash from operating activities
(9,557)
(10,428)
(10,888)
CAPEX
1
(64)
Cash from investing activities
6
(157)
Cash from financing activities
5,966
8,621
17,795
FCF
(13,494)
(11,637)
(10,849)
Balance
Cash
2,455
5,965
7,855
Long term investments
49
45
Excess cash
2,455
6,014
7,900
Stockholders' equity
(147,083)
(134,628)
(124,694)
Invested Capital
158,475
149,450
140,646
ROIC
ROCE
EV
Common stock shares outstanding
538
732
241
Price
0.52
-84.77%
3.43
127.15%
1.51
-69.37%
Market cap
281
-88.81%
2,512
589.94%
364
-35.67%
EV
(1,913)
(3,185)
(7,117)
EBITDA
(12,655)
(11,819)
(10,856)
EV/EBITDA
0.15
0.27
0.66
Interest
11
9
7
Interest/NOPBT